MRK vs ABT
By Alex · Tickerpine
Merck & Co., Inc. vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | ABT |
|---|---|---|
| Price | $147.76 | $108.52 |
| Market cap | $364.26B | $187.95B |
| P/E ratio | 149.3 | 40.5 |
| ROE | 5.06% | 9.14% |
| Profit margin | 3.64% | 9.75% |
| Revenue growth | 4.70% | 14.50% |
| Dividend yield | 2.30% | 2.32% |
| Beta | 0.12 | 0.54 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs ABT in plain English
- MRK is the bigger company — about 1.9× the market cap of ABT.
- ABT is cheaper on earnings (P/E 40.5 vs 149.3).
- ABT earns a higher return on equity (9% vs 5%).
- ABT is growing revenue faster (14% vs 5%).
- ABT has the higher dividend yield (2.32% vs 2.30%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.